Drug intelligence / Profile preview

ceftriamidine

Development stage: Unknown
Lead developer: Roche
Modality: Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration: Parenteral (likely Intravenous Or Intramuscular)

Overview

Ceftriamidine is a cephalosporin antibiotic. It is not widely marketed or approved in major regions such as the United States, Europe, or Japan. Ceftriamidine belongs to the beta-lactam class of antibiotics and acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Its primary indication would be for the treatment of bacterial infections susceptible to cephalosporins, but there is little evidence of its clinical use or approval status in major regulatory jurisdictions.

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ceftriamidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftriamidine.

Explore the full profile